MedTrace Logo

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

NCT05665075 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-01-03

No results posted yet for this study

Summary

This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML).

The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 19 patients will be enrolled.

Conditions

  • AML, Adult

Interventions

DRUG

QN-023a

NK cell therapy

DRUG

Cyclophosphamid

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Cytarabine

Lympho-conditioning Agent

DRUG

VP-16

Lympho-conditioning Agent

Sponsors & Collaborators

  • Hangzhou Qihan Biotech Co.,Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-24
Primary Completion
2023-12-24
Completion
2025-12-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05665075 on ClinicalTrials.gov